Nanobiotix (NBTX) Current Deferred Revenue (2022 - 2025)
Historic Current Deferred Revenue for Nanobiotix (NBTX) over the last 4 years, with Q2 2025 value amounting to $40.9 million.
- Nanobiotix's Current Deferred Revenue rose 5594.86% to $40.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $40.9 million, marking a year-over-year increase of 5594.86%. This contributed to the annual value of $19.6 million for FY2024, which is 5.74% up from last year.
- Latest data reveals that Nanobiotix reported Current Deferred Revenue of $40.9 million as of Q2 2025, which was up 5594.86% from $19.3 million recorded in Q4 2024.
- Nanobiotix's 5-year Current Deferred Revenue high stood at $40.9 million for Q2 2025, and its period low was $16.9 million during Q4 2022.
- In the last 4 years, Nanobiotix's Current Deferred Revenue had a median value of $19.4 million in 2023 and averaged $23.5 million.
- As far as peak fluctuations go, Nanobiotix's Current Deferred Revenue crashed by 68.26% in 2024, and later skyrocketed by 5594.86% in 2025.
- Over the past 4 years, Nanobiotix's Current Deferred Revenue (Quarter) stood at $16.9 million in 2022, then grew by 15.56% to $19.5 million in 2023, then dropped by 0.68% to $19.3 million in 2024, then soared by 111.7% to $40.9 million in 2025.
- Its Current Deferred Revenue was $40.9 million in Q2 2025, compared to $19.3 million in Q4 2024 and $26.3 million in Q2 2024.